<DOC>
	<DOCNO>NCT00840073</DOCNO>
	<brief_summary>The objective study evaluate comparative bioavailability trandolapril 4 mg tablet ( test ) MavikÂ® 4 mg Tablets ( reference ) single-dose healthy subject feed condition .</brief_summary>
	<brief_title>Trandolapril 4 mg Tablet Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Trandolapril</mesh_term>
	<criteria>Healthy , nonsmoking , male female subject , 18 year age old . BMI great equal 19 less equal 30 . Negative HIV , Hepatitis B surface antigen Hepatitis C antibody , urine drug abuse test ( marijuana , amphetamine , barbiturate , cocaine , opiates , benzodiazepine methadone ) , urine cotinine test , serum HCG consistent pregnancy ( female ) . No significant diseases clinically significant finding physical examination . No clinically significant abnormal laboratory value . No clinically significant finding 12lead electrocardiogram ( ECG ) . Blood pressure 90/60 mmHg less 140/90 mmHg . Be informed nature study give write consent prior receive study procedure . Females surgically sterile least six month postmenopausal least one year , avoid pregnancy prior study , study one month end study . Females participate study pregnant and/or nonlactating . Known history presence clinically significant medical condition . Known history food allergy , condition know interfere absorption , distribution , metabolism excretion drug . Known suspect carcinoma . Presence history angioedema . Known history presence hypersensitivity idiosyncratic reaction trandolapril and/or drug substance similar activity ; alcoholism within last 12 month ; drug dependence and/or substance abuse ; use tobacco nicotinecontaining product , within last 6 month . Any clinically significant illness surgery within 4 week prior drug administration . On special diet within 4 week prior drug administration ( e.g . liquid , protein , raw food diet ) . Participated another clinical trial receive investigational product within 30 day prior drug administration . Donated 250 mL blood within previous 30 day OR donate 251 500 mL blood previous 45 day OR donate 500 mL blood previous 56 day ( base Canadian Blood Services guideline blood donation ) . Use prescription medication within 14 day prior period 1 dosing . Use counter ( OTC ) medication within 7 day prior period 1 dosing ( except spermicidal/barrier contraceptive product ) . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoine , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior period 1 dosing . Females take oral transdermal hormonal contraceptive within 30 day precede period 1 dosing OR Females take implanted injected hormonal contraceptive ( DepoProvera ) within one year prior period 1 dosing . Difficulty fast consume standard meal . Do tolerate venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>